Expand Your Building Block Collection with Our Functionalized 1,3-Oxazoles

Our Unique Building Blocks to Perform Far and Wide
30 June 2020
Oleg Lukin
Senior Research Scientist

Although the parent 1,3-oxazole1 is not naturally occurring, a large number of substituted oxazole-containing natural products have been isolated, mostly from marine microorganisms.2 Many of these natural products are structurally complex (for example, cyclic peptide Leucamide A 13 (depicted in Fig. 1) and of considerable biological interest. Attempts at the total synthesis4 of naturally occurring derivatives have recently driven many of the discoveries of original oxazole chemistry.

On account of their versatile biological activities, oxazoles have found their use in medicine.5 Besides a few commercialized drugs, such as Oxaprozin 2 and Sulfamoxole 3 (Fig. 1), there are ca. 30 exploratory and advanced drug candidates containing the oxazole fragment.6 In organic chemistry oxazoles and their derivatives have been used as azadienes in Diels–Alder reactions7 and as ligands for asymmetric catalysts (e.g., compound 4 in Fig. 1).8

 On the relevance of the 1,3-oxazole fragment

Figure 1. On the relevance of the 1,3-oxazole fragment


We offer diversely functionalized 1,3-oxazoles for your research. Several representative title structures available from Life Chemicals are listed below. The full list of the functionalized 1,3-oxazoles is available upon request at orders@lifechemicals.com.

Life Chemicals offers diversely functionalized 1,3-oxazoles


  1. (a) Yeh, V.; Iyengar, R. in Comprehensive Heterocyclic Chemistry, 3rd edition, eds. A.R. Katritzky, C. A. Ramsden, E. F. V. Scriven, and R. J. K. Taylor Pergamon, Oxford, 2008. Vol. 4, p. 487. (b) Slobodyanyuk, E. Yu.; Volochnyuk, D. M. Chem. Heterocycl. Compounds 2019, 55, 202-204.
  2. Jin, Z. Nat. Prod. Rep. 2011, 28, 1143.
  3. König, G. M.; Kehraus, S.; Seibert, S. F.; Abdel-Lateff, A.; Müller, D. ChemBioChem 2006, 7, 229.
  4. Wang, B.; Hansen, T.M.; Weyer, L.; Wu, D.; Wang, T.; Christmann, M.; Lu, Y.; Ying, L.; Engler, M. M.; Cink, R.D.; Lee, C.-S.; Ahmed, F.; Forsyth, C. J. J. Am. Chem. Soc. 2011, 133, 1506 and references therein.
  5. (a) Joshi, S.; Bisht, A. S.; Juyal, D. Pharma Innovation 2017, 6, 109-117. (b) Downer-Riley, N. K.; Jackson, Y. A. Curr. Top. Med. Chem. 2016, 16, 3617-3626.
  6. www.drugbank.ca; accessed on July 2019.
  7. Suárez-Moreno, G.V.; González-Zamora, E.; Méndez, F. Org. Lett. 2011, 13, 6358 and references therein.
  8. Dounay, A.B.; Overman, L.E.; Wrobleski, A.D. J. Am. Chem. Soc. 2005, 127, 10186.


30 June 2020, 17:15 Oleg Lukin Building Blocks

Comments ()

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. By using our website, you accept our conditions of use of cookies to track data and create content (including advertising) based on your interest. Accept